ABL News

ABL Announces Additions to Manufacturing and Quality Control Teams

  • November 6, 2012

Rockville, MD, November 6, 2012 – Advanced BioScience Laboratories, Inc. (ABL) announces strategic hires in Upstream Process Development and Quality Control to further enhance its support of clients’ product development needs.

Yajin Ni, M.D., Ph.D., joins ABL as Senior Staff Scientist, Upstream Process Development. Dr. Ni has 15 years of combined experience in the fields of Molecular Biology & Virology, Immunology, Gene/Cell therapy and Vaccine product development, including 10 years focused on the development of gene therapy and prophylactic vaccine products. Dr. Ni holds an MD degree from Kunming Medical University as well as a PhD from Kyoto University. Prior to joining ABL, Dr. Ni served as the Director of Upstream Process Development at VIRxSYS. She also served as Director of Upstream Process Development at Yisheng US Biopharma, working at the company’s U.S. and China commercial manufacturing sites

ABL also welcomes Carol Tucker as its new Director of Quality Control. Ms. Tucker brings 18 years of experience in the biopharmaceutical and medical device fields to ABL,, with over 7 years working with bioanalytical testing and diagnostic products. Before joining ABL, Ms. Tucker was the Head of QC at Intercell USA. Ms. Tucker’s areas of expertise include cGMP compliance with US and EU requirements, contract laboratory testing oversight and stability, environmental monitoring and raw material testing programs.

“We are delighted to welcome Dr. Ni and Ms. Tucker to ABL. Dr. Ni’s proven skills in developing scalable cGMP processes for vaccine and gene therapy products complements our highly experienced manufacturing staff”, stated Andrew Arrage, Vice President of Business Development. “Ms. Tucker is a critical addition to our team. Her leadership will allow us to greatly expand our analytical assay development and testing capabilities, bringing more comprehensive development solutions to our clients.”

ABL has steadily expanded capabilities and staff over the last several years including the validation of a new cGMP facility in Rockville, MD in 2011 and securing several large multi-year government contracts and commercial projects for vaccine and biotherapeutic product development. About ABL

Advanced BioScience Laboratories, Inc. (ABL) is a Maryland-based biomedical contract research and manufacturing organization dedicated to advancing vaccines, therapeutics and other biologic products. ABL has extensive experience working with diverse organizations, including various government and academic entities and commercial biopharmaceutical companies. Notable services include basic research, product design, process and assay development, preclinical in vivo models (including immunomonitoring), and Phase I/II cGMP biologics manufacturing. Since 2001 ABL has been a part of the Institut Mérieux, a group of four companies dedicated to developing translational science for better patient care globally. For more information on ABL and our services, please visit our website at www.ablinc.com.


Advanced BioScience Laboratories, Inc.

Andrew Arrage

VP Business Development